Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2015. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific executive compensation event.
Material Changes
There are no material changes to the company's financial position reported in this filing. The only reported change is the vesting of an award for Ms. E Walmsley.
Management Commentary and Unusual Items
Executive Compensation Event: On May 1, 2015, 25% of an award made on May 1, 2010, under the GlaxoSmithKline Deferred Investment Award Plan vested for Ms. E Walmsley. This transaction results in a cash payment of 1505 pence per Ordinary share in respect of 13,669.339 notional Ordinary shares, payable on May 20, 2015. The transaction was notified in accordance with paragraph 3.1.4R(1)(a) of the Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cash payout amount for Ms. Walmsley based on the 1505 pence per share rate and 13,669.339 notional shares.
- Confirm the payment date of May 20, 2015, for the vested award.
- Review the original award terms from May 1, 2010, to understand the full vesting schedule.
- Note that this filing contains no operational or financial performance data for the period.